{"filings":[{"id":106903,"accession_number":"0001193125-26-133247","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Iterum Therapeutics to be delisted from Nasdaq on April 1 after winding-up petition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq will suspend ITRM shares at open on April 1, 2026; Form 25-NSE to follow.","Company withdrew its appeal of the prior delisting determination after filing winding-up petition on March 27, 2026.","Joint provisional liquidators Damien Murran and Jennifer McMahon (Teneo) appointed; company in provisional liquidation.","Iterum will not file Form 10-K for FY 2025 or any future SEC reports due to limited cash resources and winding-up process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106902,"accession_number":"0001193125-26-127785","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.03","2.04","5.02","7.01","9.01"],"status":"ready","headline":"Iterum Therapeutics files for winding up in Ireland; appoints provisional liquidators; CEO/CFO resign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed winding-up petition in Irish High Court; joint provisional liquidators appointed (Damien Murran, Jennifer McMahon of Teneo).","CEO Corey Fishman and CFO Judith Matthews resigned effective immediately after petition filing.","Filing triggered default under Royalty-Linked Notes; default interest rate set at prime plus 3%.","Company cites limited cash, inability to raise capital, failed strategic alternatives, and modest ORLYNVAH sales as reasons.","Nasdaq trading suspension expected March 27; shareholders likely to experience complete loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106901,"accession_number":"0001193125-26-088494","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Iterum Therapeutics requests Nasdaq hearing to appeal delisting; warns of possible wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On March 3, 2026, Iterum requested a hearing before Nasdaq Hearings Panel to appeal delisting for failure to maintain $1.00 bid price.","Hearing request automatically stays suspension scheduled for March 5, 2026, pending the hearing and any extension.","Company also fails to meet $35M minimum market value of listed securities requirement; compliance deadline June 9, 2026.","Evaluating strategic alternatives including possible wind-down, bankruptcy, licensing or sale of assets.","Company states limited ability to raise capital; shareholders very unlikely to receive distribution in a wind-down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106900,"accession_number":"0001193125-26-085646","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice; shares to suspend Mar 5, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received delisting determination letter on Feb 24, 2026 for failing minimum bid price of $1.00 per share.","Trading suspension on Nasdaq effective March 5, 2026 unless hearing requested before Nasdaq Hearings Panel.","Company evaluating appeal and strategic alternatives including possible wind-down or bankruptcy.","Also noncompliant with $35M minimum market value of listed securities and other listing standards.","Warns shareholders are unlikely to receive any meaningful distribution in a potential dissolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106899,"accession_number":"0001193125-26-057393","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Iterum shareholders reject all four EGM proposals; company warns of possible wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted against increasing authorized share capital (12.8M for vs 17.9M against).","Reverse share split proposal also defeated: 13.9M for vs 16.7M against.","Directors' allotment authority and pre-emption opt-out similarly rejected.","Company says vote results restrict ability to raise capital, harming operations and going concern.","Management warns of possible wind-down, bankruptcy, or liquidation; shareholders unlikely to receive distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123222,"accession_number":"0001193125-25-317728","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice for MVLS below $35M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Iterum on Dec 11, 2025 that MVLS <$35M for 30 consecutive business days; given 180 days until June 9, 2026 to regain compliance.","Company also remains out of compliance with $1.00 minimum bid price rule since August 2025, with compliance period ending Feb 23, 2026.","Failure to cure either deficiency could lead to delisting; company may appeal but no assurance of success.","Notice has no immediate effect on listing; common stock continues trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123221,"accession_number":"0001193125-25-281531","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.","Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.","GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.","SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.","Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":390000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123220,"accession_number":"0001193125-25-241556","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum files $20M ATM offering; ORLYNVAH launched Aug 2025 with modest sales expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for ATM offering of up to $20M aggregate gross proceeds (max ~21.8M ordinary shares).","Previously raised approximately $36.2M under same Sales Agreement with H.C. Wainwright.","ORLYNVAH commercially launched in U.S. in August 2025; company expects modest sales in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139900,"accession_number":"0000950170-25-113986","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iterum shareholders reject say-on-pay, share increase, and equity plan at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Kelly elected Class I director with 10.8M for, 2.8M against, 0.7M abstain, 8.2M broker non-votes.","Say-on-pay failed: 5.4M for (38.5%), 8.4M against, 0.5M abstain.","Share capital increase to $2.6M (add 80M shares) rejected: 6.5M for, 15.8M against.","Equity incentive plan amendment to add 4M shares rejected: 2.5M for, 11.3M against.","Allotment authority and pre-emption opt-out also failed by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.15,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139899,"accession_number":"0000950170-25-111974","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice for non-compliance with minimum bid price rule; shares traded below $1.00 for 30 consecutive business days.","180-day cure period expires February 23, 2026; must close at $1.00 for 10 consecutive business days to regain compliance.","May qualify for an additional 180-day period if it meets other listing standards and intends to cure via reverse split.","Failure to cure could lead to delisting; company will monitor options but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139898,"accession_number":"0000950170-25-110370","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Iterum launches ORLYNVAH, first oral penem antibiotic in U.S., for uUTI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved ORLYNVAH in Oct 2024; commercial launch announced Aug 20, 2025.","First oral penem antibiotic in U.S.; first new branded uUTI product in >25 years.","57% of initial uUTIs resistant to at least one antibiotic class per 2024 study.","Copay savings program allows eligible patients to get ORLYNVAH for as low as $25.","CEO cites urgent need for new oral therapies amid rising antibiotic resistance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139897,"accession_number":"0000950170-25-102394","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.","ORLYNVAH™ launch expected by end of August 2025 for uUTIs; first oral penem approved in U.S.","Entered commercialization agreement with EVERSANA; hired Christine Coyne as CCO.","Pfizer extended $20M milestone payment deferral to October 2029.","Canadian patent issued covering sulopenem/probenecid combination, expiring 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139896,"accession_number":"0000950170-25-101971","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Iterum Therapeutics enters 5-year manufacturing supply agreement with ACS Dobfar for ORLYNVAH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers commercial manufacture and supply of ORLYNVAH bilayer tablets and sulopenem etzadroxil bulk drug substance.","Initial term of 5 years with a 2-year automatic renewal; pricing based on per kg or per bottle.","Iterum Ireland provides rolling forecasts, with portion binding as firm orders; ACS to use commercially reasonable efforts for above-forecast orders.","Agreement includes customary IP protection, confidentiality, insurance, indemnification, and cGMP compliance obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139895,"accession_number":"0000950170-25-096984","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Iterum sets 2025 AGM for Sept 10; shareholder proposals due July 28","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual General Meeting scheduled for September 10, 2025.","Record date for voting eligibility is July 15, 2025.","Deadline for shareholder proposals under Rule 14a-8 is July 28, 2025.","Deadline for director nominations and other proposals is July 28, 2025.","Meeting is more than 30 days later than prior year's AGM, triggering new deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157495,"accession_number":"0000950170-25-084650","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Iterum Therapeutics enters commercialization agreement with EVERSANA for ORLYNVAH in US","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eversana will be exclusive provider of sales, marketing, logistics, regulatory, and medical affairs services for ORLYNVAH.","ITUS retains legal, regulatory, manufacturing, and books sales; pays fees and expenses per statements of work.","Term is 5 years from commercial launch; either party can terminate for material breach, insolvency, or certain law changes.","ITUS or change-of-control counterparty may terminate upon paying specified fees; Eversana can terminate if ORLYNVAH is withdrawn.","Agreement includes customary confidentiality, indemnification, and liability limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157494,"accession_number":"0000950170-25-073950","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Iterum extends $20M Pfizer milestone payment to Oct 2029; interest rises to 10%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$20M regulatory milestone due Oct 2026 extended to Oct 2029 via amended promissory note.","Interest rate increases from 8% to 10%, compounded daily, starting Oct 26, 2026.","ITIL pays Pfizer a transaction fee plus legal expenses; no senior debt or liens without Pfizer consent.","CEO says extension allows capital to be invested in ORLYNVAH launch and geographic expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157493,"accession_number":"0000950170-25-069794","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.","Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.","Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.","Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.","R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157492,"accession_number":"0001193125-25-105148","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics announces $5M registered direct offering of ordinary shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 5,555,556 shares/warrants at $0.90 each.","Net proceeds ~$4.2M after fees; H.C. Wainwright acting as placement agent.","Funding to support pre-commercialization of ORLYNVAH and strategic process, cash runway into 2026.","Offering expected to close April 30, 2025, subject to customary conditions.","Pre-funded warrants exercisable at $0.01 per share with 9.99% beneficial ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175871,"accession_number":"0000950170-25-035943","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.","Whalen joins Audit and Compensation Committees; receives annual cash retainers of $35,000 (board), $7,500 (audit), $6,000 (compensation).","David Kelly appointed Chairman of the Board effective March 10, 2025, after Ronald Hunt resigned on February 14, 2025.","Whalen's appointment restores Audit Committee to three independent members, regaining Nasdaq Listing Rule 5605(c)(2)(A) compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175870,"accession_number":"0000950170-25-021365","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Iterum Therapeutics loses audit committee compliance after Chairman Ronald Hunt resigns","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Chairman Ronald Hunt resigned Feb 14, 2025, ending 9+ year tenure; no dispute with board.","Vacancy on Audit Committee triggers non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).","Company notified Nasdaq same day; faces potential delisting if compliance not restored.","Hunt also served on compensation, nominating, and governance committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175869,"accession_number":"0000950170-25-015851","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q4 net loss $6.6M; cash $24.1M, ORLYNVAH approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $6.6M vs $12.4M in Q4 2023; full year $24.8M vs $38.4M.","Cash and equivalents $24.1M at Dec 31, 2024; including $4.8M ATM proceeds Jan-Feb 2025, runway into H2 2025.","R&D expenses fell to $1.3M in Q4 2024 from $9.7M, driven by lower REASSURE trial costs.","ORLYNVAH (sulopenem etzadroxil/probenecid) approved by FDA for uUTIs in Q4 2024; pre-commercialization underway.","Repaid outstanding 6.500% Exchangeable Notes due 2025 in January 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192778,"accession_number":"0000950170-24-135204","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics upsizes ATM offering by up to $25M, previously raised $16M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on Dec 10, 2024 for additional gross proceeds up to $25M.","Prior sales under same ATM agreement totaled approx $16M gross proceeds.","Sales agent is H.C. Wainwright & Co., LLC under agreement dated Oct 7, 2022.","Shares offered via S-3 registration statement; legal opinion from A&L Goodbody LLP attached."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192777,"accession_number":"0000950170-24-129507","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics regains Nasdaq compliance, hearing cancelled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed Iterum cured its Listing Rule 5550(b) deficiency; previously scheduled Nov 21 hearing cancelled.","Company will continue trading on Nasdaq Capital Market; avoids potential delisting.","CEO Corey Fishman expressed commitment to adhere to listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192776,"accession_number":"0000950170-24-126734","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q3 net loss $6.1M; FDA approved ORLYNVAH in October 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments totaled $14.5M at Sept. 30, 2024.","FDA approved ORLYNVAH for uUTI on Oct. 25, 2024; 10 years of GAIN Act exclusivity.","Net loss Q3 2024 was $6.1M vs $3.9M in Q3 2023; non-GAAP net loss $4.8M vs $15.7M.","R&D expenses fell to $3.1M from $14.9M due to completion of REASSURE trial enrollment.","Company seeking strategic partners for ORLYNVAH; cash expected to fund into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192775,"accession_number":"0000950170-24-120154","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Iterum issues $20M promissory note to Pfizer at 8% interest for deferred milestone payment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["FDA approved ORLYNVAH (sulopenem) on Oct 25 for uncomplicated UTIs in adult women.","$20M regulatory milestone payment triggered under 2015 Pfizer license agreement.","Company elected to defer payment for 2 years (until Oct 25, 2026) via promissory note.","Note bears 8% annual interest compounded daily; prepayable without penalty.","Upon change of control during deferral, Pfizer may accelerate full payment plus interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192774,"accession_number":"0000950170-24-117270","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Iterum receives FDA approval for ORLYNVAH for uUTIs; first product approval","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ORLYNVAH (oral sulopenem) for uUTIs in adult women with limited/no alternative oral antibiotics.","Approval based on Phase 3 trials SURE 1 (superior to ciprofloxacin) and REASSURE (non-inferior to Augmentin, statistical superiority).","ORLYNVAH is first oral penem approved in U.S. and Iterum's first FDA-approved product.","Company renews efforts for strategic transaction (sale/partnership/license) involving ORLYNVAH to maximize value.","Approximately 40M uUTI prescriptions annually in U.S.; ~1% resistant to all common oral antibiotics, addressing unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192773,"accession_number":"0000950170-24-114467","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum receives Nasdaq delisting notice, hearing set for Nov 21 on equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Iterum on Oct 1 of delisting for failing to meet $2.5M stockholders' equity requirement after Sep 30 extension deadline.","Company requested hearing; Nasdaq Hearings Panel will consider appeal on November 21, 2024.","Trading of ITRM ordinary shares continues on Nasdaq Capital Market pending hearing outcome.","Panel may grant compliance extension up to March 31, 2025, but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192772,"accession_number":"0000950170-24-113413","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iterum shareholders approve authority to issue shares without pre-emptive rights at Oct 8 EGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal to allow board to allot shares for cash without offering to existing shareholders passed with 9,785,120 votes for, 3,103,525 against, 133,633 abstain.","Approval required 75% of votes cast; threshold met with ~75.9% in favor.","Authority provides flexibility for potential future capital raises without pre-emptive obligation.","Matter considered routine under NYSE rules; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192771,"accession_number":"0000950170-24-112977","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting determination for non-compliance with stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Iterum on Oct 1, 2024 that it failed to meet terms of extension to comply with minimum $2.5M stockholders' equity requirement.","Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending hearing conclusion.","At hearing, Iterum will present a plan to regain compliance; Panel may grant extension up to March 31, 2025.","Ordinary shares continue trading on Nasdaq Capital Market under symbol ITRM pending hearing process outcome.","No assurance that Panel will grant extension or that company will ultimately regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209214,"accession_number":"0000950170-24-096649","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum reports Q2 2024 net loss $5.0M; PDUFA date Oct 25, 2024; AdCom Sept 9","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.0M Q2 2024 (vs $12.2M Q2 2023); cash $11.7M; expects runway into 2025 through PDUFA date.","FDA PDUFA action date October 25, 2024; Advisory Committee meeting September 9, 2024 on stewardship and patient population.","Closed rights offering August 9, 2024: $7.4M gross ($5.8M net) from 6.1M shares and warrants.","Received U.S. and Canadian patent allowances for sulopenem combinations expiring 2039-2041."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209213,"accession_number":"0000950170-24-092011","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics rights offering expires; expects $7.4M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights offering expired Aug 6, 2024; gross proceeds est. $7.4M, net ~$6.3M after $1.1M expenses.","17,007,601 rights distributed; each allowed purchase of 0.50 Units at $0.605.","Basic subscription: 6,121,965 Units; over-subscription of 5,091,550 Units fully honored.","Each Unit includes 1 share, 0.50 1-yr warrant ($1.21 strike), and 1 5-yr warrant ($1.21).","Shares and warrants expected to be delivered on or about Aug 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209212,"accession_number":"0000950170-24-085057","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics launches rights offering of up to $10.3M in Units at $1.21/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum 8,503,800 Units offered at $1.21/unit; each Unit includes one ordinary share, a 0.5-share 1-year warrant, and a 1-share 5-year warrant.","Subscription period July 22 to August 6, 2024; rights are non-transferable; proceeds if fully subscribed ~$10.3M.","Record date July 16, 2024; each shareholder/warrant holder receives one right per share/warrant to purchase 0.5 Units.","One eligible warrant holder waived participation; Maxim Group LLC is dealer-manager.","Rights offering previously disclosed; registration statement declared effective by SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227142,"accession_number":"0000950170-24-077963","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Iterum Therapeutics sets July 16 record date for $1.21/unit rights offering of 8.5M units","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date: July 16, 2024; subscription period expected July 22 to August 6, 2024.","Each unit ($1.21) comprises 1 ordinary share, a 1-year warrant for 0.5 shares, and a 5-year warrant for 1 share.","Basic subscription right: $0.605 for 0.5 units; over-subscription privilege available for unsubscribed units.","One eligible warrant holder waived participation; rights are non-transferable; fractional units rounded down.","Over-subscription requests allocated pro-rata if exceeded; excess payments returned without interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227141,"accession_number":"0000950170-24-075885","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Iterum Therapeutics gets FDA Advisory Committee meeting on Sept 9, 2024 for oral sulopenem NDA for uUTI","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Advisory Committee to discuss NDA for oral sulopenem (first oral penem in U.S.) for uUTI in adult women; proposed date September 9, 2024.","Discussion topics: antimicrobial stewardship issues and appropriate target patient population.","PDUFA action date set at October 25, 2024 for Class II resubmission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227140,"accession_number":"0000950170-24-066932","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Iterum receives FDA acceptance of oral sulopenem NDA resubmission; PDUFA date Oct 25, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted resubmission of NDA for oral sulopenem for uUTIs in adult women; PDUFA action date set for October 25, 2024.","Nasdaq granted 180-day extension until September 30, 2024 to regain compliance with minimum stockholders' equity requirement.","CMO Sailaja Puttagunta steps down effective May 31, 2024; will serve as consultant at $400/hour during regulatory review.","Resubmission includes REASSURE trial data showing oral sulopenem non-inferior to Augmentin and statistically superior for overall success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227139,"accession_number":"0000950170-24-058190","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum submits NDA for oral sulopenem; Q1 net loss narrows to $7.1M, cash runway into 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NDA resubmitted in April 2024 for oral sulopenem; FDA action expected early Q4 2024.","Cash, equivalents & short-term investments $18.2M at March 31, 2024; ATM raised $7.2M in Q1.","Net loss $7.1M in Q1 2024 vs $9.9M in Q1 2023; non-GAAP net loss $5.8M vs $7.4M.","R&D expenses fell to $4.0M from $6.4M as REASSURE trial enrollment completed in October 2023.","Cash runway extended into 2025, including through expected PDUFA date in early Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227138,"accession_number":"0000950170-24-057831","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Iterum CMO Sailaja Puttagunta resigns effective May 31; Steven Aronin to lead clinical development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Sailaja Puttagunta resigns for personal reasons, effective May 31, 2024; no disagreement with company.","Dr. Puttagunta will remain as consultant during regulatory review of oral sulopenem NDA for uncomplicated UTI.","Steven Aronin, SVP and Head of Clinical Development, will assume leadership of development and regulatory activities.","Transition occurs during FDA review of resubmitted NDA for oral sulopenem; potential impact on timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227137,"accession_number":"0000950170-24-049928","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum resubmits NDA for oral sulopenem to FDA for uUTIs; potential approval early Q4 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resubmitted NDA on April 29, 2024, for oral sulopenem (sulopenem etzadroxil/probenecid) for uncomplicated UTIs in adult women.","REASSURE trial showed oral sulopenem non-inferior and statistically superior to Augmentin in uUTI patients with susceptible pathogens.","SURE 1 trial demonstrated statistical superiority of oral sulopenem vs ciprofloxacin in patients with quinolone non-susceptible pathogens.","FDA review expected to complete six months from receipt; potential approval early Q4 2024, addressing July 2021 CRL deficiencies.","If approved, would be first oral penem in the U.S. and second new oral uUTI treatment in over 25 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227136,"accession_number":"0000950170-24-042288","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics receives Nasdaq delisting notice for equity deficit of $6.4M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity deficit of $6.4M as of Dec 31, 2023, below Nasdaq's $2.5M minimum.","Company must submit a compliance plan by May 20, 2024; Nasdaq may extend deadline to Sept 30, 2024.","If plan is rejected or compliance not regained, delisting proceedings may begin with appeal rights.","Iterum is evaluating options to resolve the deficiency; listing continues for now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246034,"accession_number":"0000950170-24-038414","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics posts Q4 net loss $12.4M; NDA resubmission planned early Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.4M for Q4 2023; full year 2023 net loss $38.4M; non-GAAP net loss $10.7M (Q4) and $43.8M (FY).","Cash, equivalents & short-term investments $23.9M at Dec 31; raised $7.1M post-period via ATM, extending cash runway into 2025.","NDA resubmission for oral sulopenem in uUTIs on track for early Q2 2024; FDA action expected early Q4 2024 under 6-month review.","Engaged financial advisor to explore strategic alternatives including a sale or license of sulopenem rights.","R&D expenses rose to $9.7M (Q4) and $40.0M (FY) driven by the REASSURE trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246033,"accession_number":"0000950170-24-026878","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum expects NDA resubmission for oral sulopenem in Q2 2024; cash runway into 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA resubmission for oral sulopenem to FDA expected in first half of Q2 2024, earlier than originally planned.","FDA action expected six months after resubmission (first half of Q4 2024), assuming deficiencies addressed.","Cash and equivalents as of Dec 31, 2023 plus ATM proceeds through Feb 29, 2024 expected to fund ops into 2025, including through PDUFA date.","Company plans to engage financial advisor to assist with strategic alternatives (sale, license, or disposal of rights to sulopenem)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246032,"accession_number":"0000950170-24-008937","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iterum Therapeutics shareholders reject proposal to issue up to 5M shares without pre-emptive rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal required 75% approval; received 3,139,498 For vs 2,724,101 Against and 26,719 Abstentions.","Failure to grant authority limits board's ability to quickly raise capital by issuing new shares.","Extraordinary general meeting held on January 30, 2024; vote is final.","No broker non-votes as matter was considered routine under NYSE rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246031,"accession_number":"0000950170-24-008530","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Iterum's oral sulopenem meets Phase 3 uUTI endpoint, shows superiority over Augmentin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: overall success 61.7% (sulopenem) vs 55.0% (Augmentin); 95% CI lower bound >0 showing statistical superiority.","No serious adverse events on sulopenem; discontinuations <1% in both arms; safety consistent with prior trials.","NDA resubmission planned for Q2 2024; FDA action expected in Q4 2024 if deficiencies addressed.","Company initiating strategic process to sell, license, or dispose of sulopenem rights to maximize value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263490,"accession_number":"0000950170-23-073865","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mark Chin resigns from Iterum board effective Dec 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Chin notified Company on Dec 28, 2023 of resignation from Board effective Dec 31.","Resignation due to desire to reduce public board commitments because of new job.","No disagreement with Company's operations, policies, or practices cited.","Chin served on Board for over six and a half years; Company thanked him."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263489,"accession_number":"0000950170-23-067481","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum regains Nasdaq compliance with minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter from Nasdaq on Dec 4, 2023 confirming compliance with Bid Price Rule.","Previously notified of deficiency on Sept 26, 2023; compliance deadline was March 25, 2024.","Achieved minimum $1.00 closing bid price for 10 consecutive trading days through Nov 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263488,"accession_number":"0000950170-23-063350","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum completes REASSURE enrollment; NDA resubmission for uUTI expected Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 2,229 patients in pivotal Phase 3 REASSURE trial; top-line data expected early Q1 2024.","NDA resubmission for uncomplicated UTI planned Q2 2024; FDA action expected Q4 2024.","Cash and investments $35.9M as of Sept 30, 2023; expected to fund operations into Q3 2024.","GAAP net loss $3.9M in Q3 2023 vs $29.1M in Q3 2022; non-GAAP net loss $15.7M vs $5.3M.","New composition patents for oral sulopenem granted in Korea and Australia, expiring no earlier than 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263487,"accession_number":"0000950170-23-054714","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Iterum completes enrollment in Phase 3 uUTI trial; topline data expected early Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment in REASSURE trial of oral sulopenem vs Augmentin in uncomplicated UTIs ahead of schedule.","Topline data expected early Q1 2024; NDA resubmission planned for Q2 2024 subject to data analysis.","FDA review expected within 6 months of resubmission, with action anticipated in H2 2024, if deficiencies addressed.","Sulopenem is a novel oral penem; company notes it could be first new uUTI antibiotic approved in over 25 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263486,"accession_number":"0000950170-23-050856","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Iterum Therapeutics notified of non-compliance with Nasdaq $1.00 bid price rule; 180-day cure period to March 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received deficiency notice on Sep 26, 2023 after 30 consecutive business days of closing bid price below $1.00.","Must regain compliance by March 25, 2024 by achieving $1.00 close for at least 10 consecutive business days.","May be eligible for additional 180-day cure period if meeting other Nasdaq listing standards and providing written intent to cure.","Company will consider all options, including a potential reverse share split, to address the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280710,"accession_number":"0000950170-23-041597","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Iterum Therapeutics Q2 net loss $12.2M; REASSURE trial 50% enrolled, topline data expected Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.2M in Q2 2023 vs $6.7M in Q2 2022; non-GAAP net loss $10.0M.","R&D expense $9.0M (up from $4.0M) driven by REASSURE trial costs; G&A $1.9M (down from $4.1M).","Cash and short-term investments $44.7M; cash runway into Q3 2024.","REASSURE trial: 50% enrollment (target 1,966 patients); enrollment completion expected Q1 2024, topline data Q2 2024.","New Japanese patent for oral sulopenem bilayer tablet granted; expires no earlier than 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280709,"accession_number":"0000950170-23-036485","cik":1659323,"company_name":"Iterum Therapeutics plc","ticker":"ITRMF","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Iterum Therapeutics shareholders reject proposal to authorize share issuance without pre-emptive rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At extraordinary general meeting on Aug 1, 2023, shareholders voted against granting board authority to issue ordinary shares for cash without first offering to existing shareholders.","Proposal required 75% affirmative vote; received only 3,551,455 For vs 2,167,250 Against and 31,590 Abstain.","Failure to pass limits board's flexibility to raise capital via equity offerings without statutory pre-emptive rights under Irish law.","Company had previously disclosed proposal in definitive proxy statement filed June 12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.15,"market_cap_usd":2641760.059612518,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-01T23:59:59+00:00|280709"}